secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001437749-25-033456
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q3 rev $12.9M (+12% YoY); net loss $2.0M; raises FY guidance to $50.5-52.5M
--------------------------------------------------------------------------------

- Total revenue $12.9M (+12% YoY); Surgical Aesthetics $11.1M (+19% YoY).
- Net loss attributable to stockholders $2.0M ($0.05/sh) vs $4.7M loss in Q3 2024.
- Adjusted EBITDA loss improved 96% to $0.1M from $2.4M in Q3 2024.
- FY2025 revenue guidance raised to $50.5-52.5M (prev $50-52M); Surgical Aesthetics segment guided at $43-45M.
- Initiated full U.S. commercial launch of AYON Body Contouring System; submitted 510(k) for power liposuction label expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774925033456/0001437749-25-033456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774925033456/apyx20250816_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-033456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer